Dynamic Changes in PSA Levels Predict Prognostic Outcomes in Prostate Cancer Patients Undergoing Androgen -deprivation Therapy: A Multicenter Retrospective Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 27

PMID 36845723

Authors

Mingqiu Hu

Yifeng Mao

Chao Guan

Zhizhong Tang

Zhihang Bao

Yingbang Li

Guowu Liang

Affiliations

Soon will be listed here.

Abstract

Background: Androgen-deprivation therapy (ADT) is used for the treatment of prostate cancer. However, the specific risk factors for the development of castration-resistant disease are still unclear. The present study sought to identify predictors of patient prognostic outcomes through analyses of clinical findings in large numbers of prostate cancer patients following ADT treatment.

Methods: Data pertaining to 163 prostate cancer patients treated at the Second Affiliated Hospital of Bengbu Medical University and Maoming People's Hospital from January 1, 2015, to December 30, 2020, were retrospectively analyzed. Dynamic changes in prostate-specific antigen (PSA) levels were regularly assessed, including both time to nadir (TTN) and nadir PSA (nPSA). Univariate and multivariate analyses were performed with Cox risk proportional regression models, while differences in biochemical progression-free survival (bPFS) were compared among groups with Kaplan-Meier curves and log-rank tests.

Results: The bPFS values over the median 43.5-month follow-up period differed significantly between patients with nPSA levels < 0.2 ng/mL and ≥ 0.2 ng/mL, being 27.6 months and 13.5 months, respectively (log-rank P < 0.001). A significant difference in median bPFS was also observed when comparing patients with a TTN ≥ 9 months (27.8 months) to those with a TTN < 9 months (13.5 months) (log-rank P < 0.001).

Conclusions: TTN and nPSA are valuable predictors of prognosis in prostate cancer patients after ADT treatment, with better outcomes evident in patients with nPSA < 0.2 ng/mL and TTN > 9 months.

Citing Articles

Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.

Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R Cancers (Basel). 2024; 16(18).

PMID: 39335169 PMC: 11430633. DOI: 10.3390/cancers16183198.

Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.

Lu Y, Jiang J, Yang G, Ding H, Zheng Q, Ji L Front Oncol. 2024; 14:1324181.

PMID: 38699643 PMC: 11063352. DOI: 10.3389/fonc.2024.1324181.

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.

Waseem M, Wang B Int J Mol Sci. 2024; 25(2).

PMID: 38256166 PMC: 10816550. DOI: 10.3390/ijms25021093.

References

Lin Y, Lin P, Shao I, Chu Y, Kan H, Liu C . Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy. J Oncol. 2021; 2021:9648579. PMC: 8416377. DOI: 10.1155/2021/9648579. View

Ji G, Song G, Huang C, He S, Zhou L . Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study. Medicine (Baltimore). 2017; 96(36):e7823. PMC: 6392679. DOI: 10.1097/MD.0000000000007823. View

Teoh J, Tsu J, Yuen S, Chan S, Chiu P, Lee W . Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy. Ann Surg Oncol. 2014; 22(4):1385-91. DOI: 10.1245/s10434-014-4105-8. View

Chen R, Sjoberg D, Huang Y, Xie L, Zhou L, He D . Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. J Urol. 2016; 197(1):90-96. PMC: 5503119. DOI: 10.1016/j.juro.2016.08.103. View

Huang S, Bao B, Wu M, Choueiri T, Goggins W, Liu C . Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male. 2011; 15(1):34-41. DOI: 10.3109/13685538.2011.580398. View

Fuerea A, Baciarello G, Patrikidou A, Albiges L, Massard C, Palma M . Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur J Cancer. 2016; 61:44-51. DOI: 10.1016/j.ejca.2016.03.070. View

Gravis G, Boher J, Chen Y, Liu G, Fizazi K, Carducci M . Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018; 73(6):847-855. PMC: 6010352. DOI: 10.1016/j.eururo.2018.02.001. View

Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K . Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021; 13(3). PMC: 7866532. DOI: 10.3390/cancers13030526. View

Hussain M, Tangen C, Higano C, Schelhammer P, Faulkner J, Crawford E . Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006; 24(24):3984-90. DOI: 10.1200/JCO.2006.06.4246. View

10.

Mizokami A, Izumi K, Konaka H, Kitagawa Y, Kadono Y, Narimoto K . Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian J Androl. 2016; 19(2):143-148. PMC: 5312209. DOI: 10.4103/1008-682X.179159. View

11.

Bitterman D, Chen M, Wu J, Renshaw A, Loffredo M, Kantoff P . Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. Cancer. 2021; 127(15):2623-2630. PMC: 9436009. DOI: 10.1002/cncr.33543. View

12.

Shi X, Pei X, Fan J, Liu T, Zhang D, Yang T . PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel. Andrologia. 2021; 53(4):e13916. DOI: 10.1111/and.13916. View

13.

Matsubara N, Chi K, Ozguroglu M, Rodriguez-Antolin A, Feyerabend S, Fein L . Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen.... Eur Urol. 2019; 77(4):494-500. DOI: 10.1016/j.eururo.2019.11.021. View

14.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y . Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol. 2014; 14:33. PMC: 4018264. DOI: 10.1186/1471-2490-14-33. View

15.

Teoh J, Tsu J, Yuen S, Chan S, Chiu P, Wong K . Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level. Asia Pac J Clin Oncol. 2014; 13(2):e65-e71. DOI: 10.1111/ajco.12313. View

16.

Koo K, Park S, Kim K, Rha K, Hong S, Yang S . Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int. 2015; 3(1):10-5. PMC: 4494633. DOI: 10.1016/j.prnil.2015.02.006. View

17.

Harshman L, Chen Y, Liu G, Carducci M, Jarrard D, Dreicer R . Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2017; 36(4):376-382. PMC: 5805480. DOI: 10.1200/JCO.2017.75.3921. View

18.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S . Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. Urol Oncol. 2017; 35(6):432-437. DOI: 10.1016/j.urolonc.2017.01.006. View

19.

Afriansyah A, Hamid A, Arif Mochtar C, Umbas R . Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis. F1000Res. 2018; 7:246. PMC: 5964636. DOI: 10.12688/f1000research.14026.1. View

20.

Hah Y, Lee J, Rha K, Hong S, Chung B, Koo K . Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer. Sci Rep. 2019; 9(1):11899. PMC: 6695395. DOI: 10.1038/s41598-019-48424-6. View